This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
fuboTV (FUBO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
fuboTV's (FUBO) first-quarter results are expected to reflect growth in paid subscribers and viewing supported by increased advertiser demand on the company's sports live TV streaming platform.
Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 300% and 6.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -51.21% in 4 Weeks, Here's Why You Should You Buy the Dip in Veru Inc. (VERU)
by Zacks Equity Research
Veru Inc. (VERU) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -21.05% and 50.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Asensus Surgical (ASXC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 25.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Veru Inc. (VERU): Can Its 39.5% Jump Turn into More Strength?
by Zacks Equity Research
Veru Inc. (VERU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -55.56% and 42.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Akerna Corp. (KERN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akerna Corp. (KERN) delivered earnings and revenue surprises of -16.67% and 13.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Lags Q2 Earnings Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -2.27% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Q2 Earnings Top Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 4.35% and 1.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Veru Inc. (VERU) closed at $12.10, marking a -0.9% move from the previous day.
Biotech Stock Roundup: ICPT's Study Data, NVAX Vaccine Gets EUA, VERU Up on Data
by Zacks Equity Research
Regulatory and other updates from Intercept (ICPT) and VERU are a few key highlights from the biotech sector during the past week.
Veru Inc. (VERU) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Veru Inc. (VERU) closed at $15, marking a -1.96% move from the previous day.
VERU's Shares Jump on Successful COVID-19 Study Results
by Zacks Equity Research
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Veru Inc. (VERU) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Veru Inc. (VERU) closed the most recent trading day at $11.30, moving -1.31% from the previous trading session.
Veru Inc. (VERU) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Veru Inc. (VERU) closed at $13.54 in the latest trading session, marking a +1.12% move from the prior day.
Meridian Bioscience (VIVO) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -12.50% and 14.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 26.87% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Stock Moves -1.8%: What You Should Know
by Zacks Equity Research
In the latest trading session, Veru Inc. (VERU) closed at $9.25, marking a -1.8% move from the previous day.
Earnings Preview: Veru Inc. (VERU) Q2 Earnings Expected to Decline
by Zacks Equity Research
Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.